Ozempic Face: What the Research Says

A journal issued a correction this month to a short response article about ^[1] fixing a title typo, nothing more. But the paper it corrects is worth reading on its own, because it captures a real disagreement among plastic surgeons and researchers: does semaglutide actually cause a distinct facial-aging effect, or has a catchy nickname outrun the evidence behind it?

The short answer, based on the underlying research, is that the evidence is real but thin. Rapid weight loss from any cause can hollow out the face. What is not yet established is whether GLP-1 receptor agonists (the drug class that includes semaglutide, sold as Ozempic and Wegovy) do this in a way that is different from rapid weight loss on any other diet or medication.

What the original review found

The paper at the center of this is a 2025 systematic review by Daneshgaran and colleagues in Aesthetic Surgery Journal Open Forum^[1]. A systematic review is a structured search of the published literature on a specific question, done with a defined method instead of a hand-picked reading list. The authors searched PubMed for plastic-surgery publications on GLP-1 receptor agonists and found 23 resources that fit their criteria.

Those articles described facial changes that look like accelerated aging: loss of fat volume in the cheeks and temples, and skin that has not had time to tighten back down. The review also ran the search term "Ozempic face" through Google Trends, a tool that tracks how often a phrase is searched over time, and found that spikes in that search term lined up with spikes in searches for cosmetic procedures^[1]. The authors concluded that plastic surgeons should expect more patients asking about this and should have a plan ready.

Why one researcher pushed back

Gemma Sharp, a psychologist at Adelaide University, published a formal response to the review^[2]. Her argument is not that facial volume loss during rapid weight loss is imaginary. It is that the review does not show what the popular framing of "Ozempic face" claims it shows.

Three points stand out. First, the 23 resources behind the review are mostly case reports and expert opinion, what researchers call lower-level evidence, not controlled studies that track the same patients over time. Second, hollowed cheeks and loose skin are a known consequence of losing weight quickly by any method, not something unique to semaglutide or the other GLP-1 drugs. Third, and most pointed: a rise in Google searches for a phrase measures how visible that phrase has become, not how often the underlying facial changes are actually happening. Sharp put it plainly, writing that the search-trend increase may reflect the term's visibility rather than a real increase in cases.

That is the disagreement worth understanding if you have seen "Ozempic face" described online as an established side effect of a specific drug. The more accurate framing, based on the published exchange, is that facial volume loss tracks with how much and how fast someone loses weight, and the drug used to get there is one variable among several.

What the correction actually changed

The correction itself is narrow^[3]. Sharp's response was originally published under the title "Response by Sharp to 'Ozempic Face': Construct, Consequence, or Clinical Entity?" On 17 September 2026 the journal corrected that title to match the review it was actually responding to. The scientific content of the response was not changed. It is a bibliographic fix, not a retraction or a new finding, and it is easy to overread a correction notice as bigger news than it is.

What plastic surgeons are doing in practice

Whatever the underlying cause, patients are showing up asking about it, and the American Society of Plastic Surgeons^[4] describes a mix of nonsurgical and surgical responses: dermal filler and fat transfer to restore volume, collagen-stimulating treatments for skin quality, and, for more pronounced skin laxity, a facelift combined with fat grafting. None of these are a response to the drug itself. They are the same tools plastic surgeons already use for volume loss and skin laxity from any cause, applied to a wider group of patients because more people are now losing weight quickly with semaglutide and related medicines.

If you are considering semaglutide or a related drug like tirzepatide and are weighing facial appearance among your concerns, that is a conversation for a prescribing clinician and, separately, a board-certified plastic surgeon or dermatologist, not something to plan around a term you saw on social media.

What we don't yet know

Nobody has yet run the controlled, long-term study that would settle this cleanly: following a group of patients on GLP-1 therapy against a matched group losing similar weight another way, tracking facial volume with objective measurement rather than before-and-after photos. Sharp's response calls for exactly that kind of longitudinal, objective research, and until it exists, claims that semaglutide has a facial-aging effect distinct from weight loss itself are a hypothesis under active debate, not a settled finding.